Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics

  • Kim, Kiwan; 
  • Song, Seong-Won; 
  • Jeon, Yeongha; 
  • Choi, Soyoung; 
  • Choi, Jiyoun; 
  • 외 9명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0

초록

Purpose: This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor alpha 2 (IL13R alpha 2) in patients with malignant gliomas.Patients and Methods: Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13R alpha 2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS).Results: Ten patients were sequentially assigned to 3 dosing cohorts (1 & times; 107, 3 & times; 107, and 1 & times; 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade <= 3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3-14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95-5.75], and the median OS was 10.9 months (95% CI, 8.2-26.6).Conclusions: Intravenous IL13R alpha 2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.

키워드

INTERLEUKIN-13 RECEPTOR ALPHA-2; CHIMERIC ANTIGEN RECEPTORS; IL-13 RECEPTOR; GLIOBLASTOMA; EXPRESSION; GROWTH; CANCER
제목
Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
저자
Kim, Kiwan; Song, Seong-Won; Jeon, Yeongha; Choi, Soyoung; Choi, Jiyoun; Jun, Sungmin; Park, Ju-Hwang; Lee, Song-Jae; Han, Nayoung; Dho, Yun-Sik; Shin, Sang-Hoon; Yoo, Heon; Wang, Kyu-Chang; Gwak, Ho-Shin
DOI
10.1158/1078-0432.CCR-26-0645
발행일
2026-10-15
유형
Article
저널명
Clinical Cancer Research
권
32
호
20
페이지
4656 ~ 4667